RG 4929

Drug Profile

RG 4929

Alternative Names: 11 Beta HSD inhibitor; R4929; RG4929; RO 5093151

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action 11-beta-hydroxysteroid dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glaucoma; Ocular hypertension
  • Discontinued Non-alcoholic fatty liver disease; Type 2 diabetes mellitus

Most Recent Events

  • 31 Jul 2016 Roche completes a phase I trial in Glaucoma and Ocular hypertension USA and Singapore (Ophthalmic, Liquid) (NCT02622334)
  • 01 Nov 2015 Phase-I clinical trials in Glaucoma and Ocular hypertension in USA (Ophthalmic) (NCT02622334)
  • 16 Oct 2012 Discontinued - Phase-I for Non-alcoholic fatty liver disease in Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top